Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian population (Mazandaran)

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 11, 2011, Pages 821-825

  Hashemi Soteh, Seyed Mohammad Bagher ^a   Sarzare, Fatemeh ^b   Merat, Fatemeh ^b   Salehifar, Ebrahim ^b   Shiran, Mohammad Reza ^c  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; GENOMIC DNA;

ADOLESCENT; ADULT; ARTICLE; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRAN; MALE; NORMAL HUMAN;

ADOLESCENT; ADULT; ALLELES; CHILD; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENOTYPING TECHNIQUES; HUMANS; IRAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 81755171121     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0033     Document Type: Article

References (38)

1. Afshar M, Rouini M, et al. (2005) Dextromethorphan metabolic phenotyping in an Iranian population. Eur J Clin Pharmacol 60:849-854. (Pubitemid 40386154)
2. Agundez JA, Ledesma MC et al. (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phe-notype in a white population. Clin Pharmacol Ther 57: 265-269.
3. Aydin M, Hatirnaz O, et al. (2005) CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem Funct 23: 133-135. (Pubitemid 40363685)
4. Bathum L, Skjelbo E, et al. (1999) Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48:395-401. (Pubitemid 29417724)
5. Bernal ML, Sinues B, et al. (1999) Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Phar-macogenetics 9:657-660.
6. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192-209.
7. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharma-cogenomics 3:229-243. (Pubitemid 34223859)
8. Bradford LD, Gaedigk A, et al. (1998) High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull 34:797-804. (Pubitemid 29497928)
9. Chida M, Yokoi T, et al. (1999) Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 9:601-605.
10. Dahl ML, Yue QY et al. (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5:159-164.
11. Fuselli S, Dupanloup I, et al. (2004) Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 12:916-924. (Pubitemid 39462125)
12. Gawronska-Szklarz B, Wojcicki M, et al. (1999) CYP2D6 and GSTM1 genotypes in a Polish population. Eur J Clin Pharmacol 55:389-392. (Pubitemid 29344083)
13. Griese EU, Asante-Poku S, et al. (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9:715-723. (Pubitemid 30011935)
14. Griese EU, Zanger UM, et al. (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26. (Pubitemid 28097597)
15. Hashemi Soteh M, Peake IR, et al. (2007) Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. Haemato-logica 92:550-553. (Pubitemid 350144301)
16. Ingelman-Sundberg M (2005) Genetic polymorphisms of cyto-chrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13. (Pubitemid 40220611)
17. Jaanson P, Marandi T, et al. (2002) Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 162:67-73. (Pubitemid 34639559)
18. Ji L, Pan S, et al. (2002) Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J (Engl) 115:1780-1784. (Pubitemid 36105051)
19. Johansson I, Oscarson M, et al. (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459. (Pubitemid 24296678)
20. Johansson I, Yue QY, et al. (1991) Genetic analysis of the inter-ethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 40:553-556.
21. Kouhi H, Hamzeiy H, et al. (2009) Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test Mol Biomarkers 13:665-670.
22. Kubota T, Yamaura Y, et al. (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34. (Pubitemid 30416968)
23. Leathart JB, London SJ, et al. (1998) CYP2D6 phenotype-geno-type relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541. (Pubitemid 29043386)
24. Lopez M, Guerrero J, et al. (2005) CYP2D6 genotype and phe-notype determination in a Mexican Mestizo population. Eur J Clin Pharmacol 61:749-754. (Pubitemid 41674261)
25. Marez D, Legrand M, et al. (1997) Polymorphism of the cyto-chrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202. (Pubitemid 27290633)
26. McLellan RA, Oscarson M, et al. (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacoge-netics 7:187-191. (Pubitemid 27290632)
27. Menoyo A, del Rio E, et al. (2006) Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 24:381-385. (Pubitemid 44379576)
28. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671.
29. Naveen AT, AdithanC,etal. (2006) CYP2D6 genetic polymorphism in South Indian populations. Biol Pharm Bull 29:1655-1658. (Pubitemid 44166369)
30. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448. (Pubitemid 34311090)
31. Sachse C, Brockmoller J, et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295. (Pubitemid 27058401)
32. Smith CA, Gough AC, et al. (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377.
33. Wan YJ, Poland RE, et al. (2001) Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11:489-499. (Pubitemid 32778227)
34. Wang SL, Huang JD, et al. (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418.
35. Wennerholm A, Johansson I, et al. (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707-714. (Pubitemid 30011934)
36. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
37. Zanger UM, Raimundo S, et al. (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37. (Pubitemid 38161221)
38. Zhou Q, Yu XM, et al. (2009) Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J 9:380-394.